NCT07414979 is a Phase 1 clinical trial of CD8+T cells in Leptomeningeal Melanoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT07414979?

NCT07414979 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT07414979?

Interventions in NCT07414979: CD8+T cells.

What condition does NCT07414979 study?

NCT07414979 studies Leptomeningeal Melanoma.

Is NCT07414979 still recruiting?

NCT07414979 is currently not yet recruiting. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT07414979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma

Not yet recruiting Phase 1 Last updated 17 February 2026

What this trial tests

Phase 1 trial testing CD8+T cells in Leptomeningeal Melanoma in 8 participants. Not yet recruiting.

Timeline

31 August 2026

Primary endpoint
22 March 2028

22 March 2030

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	31 August 2026
Primary completion	22 March 2028
Estimated completion	22 March 2030
Sites	1 location across United States

Drugs / interventions tested

CD8+T cells — full drug profile →

Conditions studied

Leptomeningeal Melanoma — all drugs for Leptomeningeal Melanoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Leptomeningeal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A\*0201+ and HLA-A\*24 02+ individuals with leptomeningeal disease from metastatic melanoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07414979 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07414979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing